Biotech Co.* (Country; Symbol) |
Pharma Co. |
Type/Product Area |
Terms/Details (Date) |
| |||
Abgenix Inc. (ABGX) |
Sosei Corp. Ltd. (Japan) |
Agreement focusing on fully human monoclonal antibody therapies against CRTH2 |
The companies will co-develop antibodies against CRTH2 and additional target antigens that might be contributed; they will share development and manufacturing costs for antibody products; Abgenix will use its XenoMouse technology to generate, screen and characterize human monoclonal antibodies; Sosei will be responsible for commercialization in Japan, while Abgenix would lead commercialization in the U.S.; profits would be shared equally (3/31) |
|
|||
Advanced |
Smith & Nephew plc (UK)
|
Agreement for Advanced Tissue to sell additional fixed assets and intellectual property rights to the wound management unit of Smith & Nephew |
The agreement covers transferring certain research and development equipment and assets related to the manufacturing of collagen; Smith & Nephew will pay Advanced Tissue $700,000 (4/29) |
|
|||
Astex |
Schering AG (Germany) |
Four-year, multi-target agreement to discover drugs for various therapeutic indications |
The agreement will focus on orally available, small-molecule drugs targeting solid tumors; Schering will fund Astex's related research, providing discovery and clinical milestone payments plus sales-based royalties on approved products; Schering will be responsible for clinical development and retains an option for worldwide exclusive marketing rights for all identified compounds (5/6) |
|
|||
Biovation Ltd.* (UK) |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Research agreement under which Biovation will apply its DeImmunisation technology to generate biopharmaceuticals |
Biovation will receive research fees and could earn license fees, milestone payments and royalties (5/21) |
|
|
|
|
CeNeS Pharmaceuticals plc (UK; LSE:CEN) |
Waymade Healthcare plc (UK) |
Agreement to sell Diconal, Cyclimorph and Valoid to Waymade |
CeNeS received more than £9M (US$14.2M) in cash for the products, which were acquired from GlaxoWellcome in September 2000 and are sold mainly to hospitals to treat post-operative pain and/or nausea and vomiting (4/16) |
|
|
||
Chiron Corp. (CHIR) |
Novartis AG (Switzerland) |
Exclusive worldwide development and commercial agreement for aerosolized cyclosporine, or ACsA |
Chiron gains rights to the product, which is under evaluation for the treatment of acute rejections in lung transplant recipients (4/22) |
|
|||
Chiron Corp. (CHIR) |
West Pharmaceutical Services Inc. |
Development and worldwide licensing agreement to produce and commercialize a diphtheria and tetanus nasal vaccine using West's ChiSys nasal drug delivery technology with Chiron Vaccines, the vaccine division of Chiron |
West will receive development fees and milestone payments, as well as potential royalties; Chiron will be responsible for regulatory filings, marketing and commercialization activities (3/25) |
|
|||
CompleGen Inc.* |
Berlex Laboratories Inc. (unit of Schering AG; Germany) |
Research collaboration in which CompleGen is supplying Berlex with a high-throughput assay system to discover compounds against a novel target identified by Berlex using CompleGen's XenoGene system |
CompleGen has rights downstream based on discovering and commercializing useful compounds (4/8) |
|
|
|
|
CyDex Inc.* (Israel) |
Teva Pharmaceutical Industries Ltd. |
Licensing agreement giving Teva rights to Captisol, an advanced formulation system for a peptide-based drug candidate under development for treatment of systemic lupus erythematosus |
CyDex granted Teva global rights for the use of Captisol in a formulation of TV-4710 (4/30) |
|
|||
Cytokine PharmaSciences Inc.* |
Integrity Pharmaceutical Corp. |
Agreement to exclusively license U.S. rights to Cytokine's second-generation cervical ripening product to Integrity |
Cytokine, which will receive an undisclosed up-front payment, milestones and royalties, will manage all clinical work before a new drug application is filed, while Integrity will share expenses (4/3) |
|
|||
DeCode genetics Inc. (Iceland; DCGN) |
AstraZeneca plc (UK) |
Agreement for AstraZeneca to purchase DeCode's RoboHTC automated protein crystallo- graphy platform |
Financial terms were not disclosed (4/8) |
|
|||
Epimmune Inc. (EPMN) |
Merck & Co. Inc. |
Agreement in which Merck will evaluate Epimmune's epitopes in connection with its own technology for the development of vaccines |
Merck is interested in developing the technology for multiple indications (5/1) |
|
|||
Evotec OAI AG (Germany; Neuer Markt:EVT) |
Novartis AG (Switzerland) |
Assay development and screening contract to identify drug candidates for several undisclosed targets |
Further details were not disclosed (4/10) |
|
|||
Gene Logic Inc. (GLGC) |
Novartis AG (Switzerland) |
Subscription agreement for Gene Logic's toxicogenomics information product, the ToxExpress Predictive System |
The multiyear agreement gives Novartis access to the full complement of reference gene expression content and predictive models within the ToxExpress Predictive System (4/21) |
|
|||
GlycoFi Inc.* |
Baxter Healthcare Corp. |
Collaboration under which Baxter will evaluate the potential of GlycoFi's fungal expression platform for the production of human therapeutic proteins |
Financial terms were not disclosed (5/21) |
|
|||
Guilford Pharmaceuticals Inc. (GLFD) |
Pfizer Inc. |
Licensing agreement for Pfizer to develop Guilford's N-acetylated-alpha-linked- acidic-dipeptidase inhibitors worldwide |
Pfizer agreed to pay $15M, including $5M up front and the remaining $10M by next March 31, if a lead compound is selected (5/8) |
|
|||
Iconix Pharmaceuticals Inc.* |
Eisai Co. Ltd. (Japan) |
Agreement to provide chemo-genomic profiling and analytical services |
Scientists will collaborate to gain a chemogenomic understanding of Eisai's early stage drug candidates to better predict their pharmacology and toxicology before clinical development (4/14) |
|
|
||
Idenix Pharmaceuticals Inc.* |
Novartis Pharma AG (Switzerland) |
Licensing agreement for Idenix's hepatitis B drug candidates, which include telbivudine and valtorcitabine |
Novartis will assume global clinical development costs and will be responsible for regulatory filings outside the U.S.; the deal could be worth up to $862M; Novartis is acquiring a 51% stake in Idenix for $255M and will make a $75M up-front payment; Idenix could receive up to $357M in milestone payments; Novartis has an option to jointly develop NM283, which, if exercised, could result in another $175M in milestone payments (3/26) |
|
|||
Immune Network Ltd. (Canada; OTC BB: IMMFF) |
NV Organon (the Netherlands) |
Agreement for Immune Network to access structural and biological data and samples of 120 compounds belonging to NV Organon |
If such studies generate hits, Immune Network will begin preclinical development, after which the parties would negotiate a separate collaboration or license agreement (4/28) |
|
|||
Flamel Technologies SA (France; FLML) |
GlaxoSmithKline plc (UK) |
Licensing agreement for Flamel's controlled-release Micropump technology |
GlaxoSmithKline plans to develop a new formulation for an undisclosed existing product; Flamel will receive an up-front payment of $2M and additional milestone payments upon achievement of certain events, as well as royalties on product sales - payments that could range up to $45M by the end of the first year following launch (3/28) |
|
|||
Indevus Pharmaceuticals Inc. (IDEV) |
Aventis SA (France) |
Agreement giving Indevus worldwide rights to an antifungal compound |
Indevus gained rights to aminocandin and is responsible for all development and commercialization activities for both intravenous and oral formulations of aminocandin on a worldwide basis; Aventis will manufacture a key component of aminocandin; Indevus will make an up-front licensing payment to Aventis, as well as milestone payments and royalties (4/23) |
|
|||
Jerini Peptide Technologies* (subsidiary of Jerini AG; Germany) |
Bayer AG (Germany) |
Agreement for Jerini to provide large libraries of peptides for high-throughput screening on specific drug targets |
Bayer will use Jerini's SPOT technology; financial terms were not disclosed (5/21**) |
|
|||
Kalypsys Inc.* |
Merck & Co. Inc. |
Agreement giving Merck access to Kalypsys' high-throughput lead discovery system |
The companies will collaborate to extend the system's capabilities (3/25) |
|
|
||
Lexicon Genetics Inc. (LEXG) |
Aventis Pharmaceuticals Inc. |
Licensing agreement for nonexclusive rights to Lexicon's gene targeting technologies |
Aventis will use the technologies in its internal research programs (4/22) |
|
|||
Locus Pharmaceuticals Inc.* |
Speedel Group (Switzerland) |
Collaboration to design and develop renin inhibitors |
Locus will apply its computational technology to design small-molecule renin inhibitors for further development by Speedel, which will reimburse Locus' research costs and also make milestone and royalty payments (4/29) |
|
|
||
Medarex Inc. (MEDX) |
Pfizer Inc. |
Partnership to develop fully human therapeutic antibodies |
Medarex will use its UltiMAb Human Antibody Development System to generate antibodies to disease targets, and could receive license fees and milestone payments, as well as royalties (4/16) |
|
|||
Medivir AB to (Sweden; SSE:MVIRb) |
GlaxoSmithKline plc (UK) |
Licensing agreement for Medivir's MIV-210 |
GlaxoSmithKline paid €6M in an up-front payment; it plans to continue develop the nucleoside analogue reverse transcriptase inhibitor for HIV, in which it has begun Phase I development; GSK will make milestone payments up to €86M and gained exclusive worldwide rights to the compound except in Denmark, Finland, Iceland, Norway and Sweden; Medivir will receive undisclosed royalties on eventual sales (5/20) |
|
|||
Morphochem |
MCS Micro Carrier Systems GmbH (Germany) |
Agreement to speed animal testing of Morphochem's lead drug candidates |
MCS will formulate new chemical compounds using what the companies described as pharmaceutically relevant and acceptable components in the delivery systems design (3/28) |
|
|||
Neose Technologies Inc. (NTEC) |
GlaxoSmithKline plc (UK) |
Agreement to license certain intellectual property rights to GlaxoSmithKline |
GSK gained an exclusive license to develop, produce and sell certain human vaccines for the prevention, control or treatment of undisclosed diseases; it also has non-exclusive rights to use any other patents owned by Neose that are needed to practice its rights in the same field; Neose will receive undisclosed license fees, milestone payments and royalties (4/30) |
|
|||
Neurogenetics Inc.* |
Eli Lilly & Co. |
Licensing agreement for exclusive worldwide rights to a first-in-class molecule owned by Lilly that has demonstrated efficacy across pain models |
The compound is an AMPA/Kanate receptor antagonist that has been studied in patients with migraines, chronic lower back pain and pain associated with spinal cord trauma; Lilly will receive an up-front fee, success-based milestone payments and royalties on sales (5/6) |
|
|||
NiKem Research Srl* (Italy) |
Wyeth Pharmaceuticals |
Research services agreement in which NiKem will use its medicinal chemistry know ledge to provide the synthesis of chemical compounds |
The compounds will complement and diversify the tools used by Wyeth to screen potential new drug candidates (5/12) |
|
|||
Noven Pharmaceuticals Inc. (NOVN) |
Procter & Gamble Co. |
Agreement to develop new prescription transdermal delivery systems for P&G Pharmaceuticals Inc., a subsidiary of Procter & Gamble |
Noven is entitled to receive up to $7.8M, payable in installments if certain development milestones are achieved (4/30) |
|
|||
Protein Pathways Inc.* |
Merck & Co. Inc. |
Research collaboration in which Merck will apply Protein Pathways' ProNexus technology to its drug discovery efforts |
Financial terms were not disclosed (4/2) |
|
|||
Regeneron Pharmaceuticals Inc. (REGN) |
Novartis AG (Switzerland) |
Agreement for Regeneron's Interleukin-1 Trap technology |
Novartis is paying $27M in cash and making a $48M equity investment in Regeneron through a stock purchase, with the potential for $275M more in milestone payments; profits in North America and Europe will be split, along with promotion rights; development costs in 2003 will be shared; after that, Novartis will pay pre- Phase III development expenses; Regeneron retains full rights in Japan; companies will have co-promotion rights in other regions, with Novartis getting 75% of the profits (3/28) |
|
|||
Serenex Inc.* |
GlaxoSmithKline plc (UK) |
Agreement to incorporate Serenex's chemoproteomics technologies into selected GSK drug discovery programs |
The agreement provides GSK with access to Serenex's Proteome Mining and Functional Proteome Fractionation technologies to screen GSK compounds against protein targets (5/5) |
|
|
||
SkyePharma plc (UK; SKYE; LSE:SKP) |
King Pharmaceuticals Inc. |
Licensing agreement to develop and commercialize a modified-release formulation of King's product Altace using SkyePharma's oral, controlled-release Geomatrix drug delivery technology |
King is paying SkyePharma $1M up front, potential milestones of $6.5M, reimbursing expenses and paying royalties on sales of any resulting products (5/19) |
|
|||
Structural GenomiX Inc.* |
Eli Lilly and Co. |
Agreement to install a gene-to-structure technology for Lilly in a high-throughput structural biology facility |
Structural GenomiX will apply the technology platform to certain Lilly drug targets to determine their 3-dimensional structures (4/21) |
|
|||
SurroMed Inc.* |
Wyeth |
Biomarker discovery agreement in which Wyeth will supply clinical samples for analysis in SurroMed's BioMarker Discovery Laboratory |
SurroMed will analyze the samples using its SurroScan microvolume laser-scanning cytometry system (4/2) |
|
|
||
Symyx Technologies Inc. (SMMX) |
BP plc (UK) |
Two-year research and development collaboration to discover catalysts relevant to BP's commodity chemical businesses |
BP will fund Symyx's discovery efforts and has exclusive rights to commercialize resulting materials, while Symyx will receive royalties in connection with the sale of those products (3/27) |
|
|||
Symyx Technologies Inc. (SMMX) |
Merck & Co. Inc. |
Agreement for the development, purchase and license of a Discovery Tools Process Optimization Workflow for preclinical development use |
Financial terms were not disclosed (4/17) |
|
|||
Telik Inc. |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Collaboration to use TRAP to identify drug candidates active against a Roche pharmaceutical target |
Financial terms were not disclosed (4/10) |
|
|||
VistaGen Therapeutics |
Sanwa Kagaku Kenkyusho Co. (Japan) |
Multiyear research partnership to develop stem cell-based discovery tools |
VistaGen will receive up-front technology license fees, an equity investment and several years of funded research (4/8) |
|
|||
Vivalis* |
Aventis Pasteur (unit of Aventis SA; France) |
Research, option and license agreement in which Vivalis will combine its avian stem cell platform with Aventis' Alvac canary-pox virus platform in an effort to improve large-scale production of several Alvac vaccine candidates in the fields of HIV and cancer |
The companies signed an option allowing Aventis to use Vivalis stem cell lines for the production of another undisclosed virus vaccine (5/6) |
|
|||
Xenogen |
Bristol-Myers Squibb Co. |
Nonexclusive licensing agreement for Xenogen's realtime imaging technology accompanied by an IVIS Imaging System |
Under a separate agreement, BMS will grant Xenogen a nonexclusive license to use Xenogen's real-time biophotonic imaging technology and Xenogen Bioware cells and microorganisms in its research; BMS granted Xenogen rights to use Cre-Lox for its own research, as well as to include it as a commercial service offering (5/12) |
|
|||
Zealand Pharma A/S* (Denmark) |
Wyeth |
Development and license agreement in which the companies will co-develop ZP123 to treat arrhythmias and other cardiovascular diseases |
The companies will conduct preclinical studies, while Wyeth would conduct future clinical development; Zealand will receive research funding and milestone payments, as well as royalties (5/1) |
|
|||
| |||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
** Denotes the date the item ran in BioWorld International. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange |